Cardiovascular Consequences of Inhaled Short-acting Beta-agonist Use

NCT06027606 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

81

Enrollment

OTHER

Sponsor class

Conditions

Healthy

Interventions

DRUG: Salbutamol 400mcg
DRUG: Budesonide/formoterol
DRUG: Placebo

Sponsor

University of Alberta